Overview
EpicentRx is a biopharmaceutical company developing innovative therapies for oncology and related conditions, including the oncolytic virus-delivered TGFβ inhibitor AdAPT-001 and the small molecule RRx-001 (nibrozetone). Both lead candidates have received FDA Fast Track designations: AdAPT-001 for recurrent/refractory soft tissue sarcoma in combination with checkpoint inhibitors, and RRx-001 for severe oral mucositis prevention and other indications. Their platforms target tumor sensitization, immune modulation, inflammation reduction, and side effect mitigation across cancers like STS, colorectal, breast, and head/neck.
Frequently asked questions
- What are EpicentRx's lead drug candidates?
- AdAPT-001, an oncolytic adenovirus-delivered TGFβ inhibitor for immunotherapy sensitization in cancers like soft tissue sarcoma, and RRx-001 (nibrozetone), a small molecule with anti-inflammatory, Nrf2-activating, and nitric oxide-releasing properties for oral mucositis prevention and oncology.
- What regulatory designations has EpicentRx received?
- FDA Fast Track for AdAPT-001 in recurrent/refractory soft tissue sarcoma combined with nivolumab or atezolizumab, and for RRx-001 in severe oral mucositis and other trials; also a US Department of Defense award for RRx-001 neuroprotection.
- What is the therapeutic focus and pipeline stage?
- Focus on oncology (solid tumors, immunotherapy resistance), side effect reduction (mucositis), and emerging areas like neuroprotection and endometriosis; both leads are in late-stage (Phase 2/3) clinical trials.